CD8A and cancer: Therefore, immunotherapy that involves the activation of both CD8α+CD11c+ and CD8α−CD11c+ cDCs by cancer Ags combined with an adjuvant may elicit both CTL and Th immune responses against cancer cells, thereby improving the efficacy of the treatment.